SIRT5 and cancer: Further work will be required to test the efficacy of potential SIRT5 inhibitors (19–21) in models of cancer (18, 22) and of infections and sepsis, then to define whether these inhibitors may predispose to infections in the setting of comorbidities, e.g., in elderly patients and patients with chronic inflammatory disorders like for example colitis and diabetes mellitus.